Evidence map›Paper›PMID 41798677›Full record

ArticleBlood neoplasia2026

Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes.

Nicholas Chornenki, Afraa Fadul, Analiza Supan, Yasser Abou Mourad, Hannah Cherniawsky, Shanee Chung, Donna Forrest, Deepesh Lad, Aly Karsan, Florian Kuchenbauer and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nicholas ChornenkiDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Afraa FadulDepartment of Hematology-Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Analiza SupanLeukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer and Vancouver General Hospital, Vancouver, BC, Canada.
Yasser Abou MouradDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Hannah CherniawskyDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Shanee ChungDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Donna ForrestDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Deepesh LadDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Aly KarsanDepartment of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada.
Florian KuchenbauerDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Eric McGinnisDepartment of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada.
Stephen NantelDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Sujaatha NarayananDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Thomas NevillDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Judith RodrigoDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Claudie RoyDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Kevin SongDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Cynthia TozeDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Jennifer WhiteDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
David SanfordDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Ryan J StubbinsDivision of Hematology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a high-risk AML subtype defined by cytogenetic or genetic changes. We evaluated the relevance of AML-MRC classifications in a contemporary cohort of intensively treated patients with AML. We retrospectively reviewed 496 consecutive patients receiving induction chemotherapy for AML between 2016 and 2023 at a single center. Patients were categorized using both World Health Organization 2017 (MRC-2017) and International Consensus Classification 2022 (MRC-2022) criteria. Outcomes were compared using χ

Identifiers

PMID41798677
PMCPMC12966869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.